Trubogli Forte
New Armamentarium for PPHG Management


Composition : Voglibose 0.2mg + Repaglinide 1mg

Form : Tablets / Pack : 1 x 10"s / Type : A A

Description : A non-randomized, open labeled, non-comparative, single-centric study was conducted in total of 20 type 2 diabetes mellitus (T2DM) patients (9 men and 11 women, mean age 69.07 ± 3.495 years). Each patient was administered a fixed dose combination of voglibose 0.3mg & repaglinide 0.5/1mg three times a day, just before each meal for 30 days. Fasting blood glucose (FBG) & postprandial blood glucose (PPBG) was performed at baseline & at the end of study as assessment tools. At the end of study data was extractable only in 15 patients because 5 patient dropped out as they did not turn up for follow up at day 30.Postprandial blood glucose reduced significantly {-61.67mg/dl (95% confidence interval -76.79 to -46.54 p<0.0001)} from baseline at day 30. Also a significant reduction (p<0.0001) was found with FBG {-42.13mg/dl (Confidence interval -61.25 to -23.02 P value <0.0001)} at end of day 30. There were no adverse events reported including hypoglycemia. Voglibose and Repaglinide combination was effective and safe for the management of PPHG in T2DM patients- Global Journal of Obesity, Diabetes and Metabolic Syndrome- 2017

View more products with following salts